Rationale, application and clinical qualification for NT-proBNP as a surrogate end point in pivotal clinical trials in patients with AL amyloidosis

Amyloid light-chain (LC) amyloidosis (AL amyloidosis) is a rare and fatal disease for which there are no approved therapies. In patients with AL amyloidosis, LC aggregates progressively accumulate in organs, resulting in organ failure that is particularly lethal when the heart is involved. A signifi...

Descripción completa

Detalles Bibliográficos
Autores principales: Merlini, G, Lousada, I, Ando, Y, Dispenzieri, A, Gertz, M A, Grogan, M, Maurer, M S, Sanchorawala, V, Wechalekar, A, Palladini, G, Comenzo, R L
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2016
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5056962/
https://www.ncbi.nlm.nih.gov/pubmed/27416985
http://dx.doi.org/10.1038/leu.2016.191

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5056962/
https://www.ncbi.nlm.nih.gov/pubmed/27416985
http://dx.doi.org/10.1038/leu.2016.191

Ejemplares similares